Fri, Dec 26, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Hedge funds post net returns of 1.72%; (1.42% YTD) - Preqin

Tuesday, March 18, 2014
Opalesque Industry Update - Using data taken from Preqin’s Hedge Fund Analyst, hedge funds added gains of 1.72% in February which takes the industry benchmark to 1.42% for the year to date. Despite gains of over 2% for some hedge fund strategies, hedge funds lagged wider equity markets and indices, such as the S&P 500 which was up over 4% in February 2014.

Other Key Facts:

  • Event driven funds were the top performing funds in February, making gains of 2.67% and continuing their eight month streak of positive performance.
  • Relative value funds added just 0.83% in February 2014, despite being the top performing fund strategy in January and one of the two strategies to post positive returns in the first month of the year.
  • Emerging markets-focused funds were in positive territory in February, adding net returns of 0.94%; however, this was not sufficient to regain losses of 2.10% in January and its YTD returns of -1.18% makes it the only regional benchmark in the red for 2014.
  • Funds of hedge funds focused on macro strategies have outperformed single-manager macro strategies funds YTD, each posting net returns of 1.27% and 0.19% respectively.
  • CTAs returned to positive territory, adding 1.76% in February 2014, following net losses of 1.01% in January. This is the benchmark’s first monthly return of over 1.50% since July 2012.
  • North America-focused funds posted the highest returns of all regional benchmarks, adding 2.55% in February. This is compared to 1.79% for Europe and 1.28% for Asia-Pacific.

Comment:

“Investors may be reassured that the widespread negative returns across many of Preqin’s hedge fund performance benchmarks in January look to be a temporary blip rather than the start of a longer downward trend. Much of the January losses were led by declining equity markets which struggled at the start of the year following concerns around emerging markets and following the storms in the US.

However, equity benchmarks improved in February, with indices such as S&P 500 reaching record levels; strategies which have a focus on equities, in turn, also saw strong performance for the month. Event driven and long/short funds both posted returns of over 2% in February, taking their 12-month net returns to 16.04% and 11.91% respectively.”

Amy Bensted, Head of Hedge Fund Products - Preqin

Press Release

BM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its